medigraphic.com

2004, Number 3

<< Back Next >>

Med Sur 2004; 11 (3)

Detection of serum antibodies against Trypanosoma cruzi in blood donors

Baptista GH, Santamaría HC, Cedillo VF, Bordes AJ

Language: Spanish
References: 32
Page: 169-174
PDF size: 75.75 Kb.


ABSTRACT

Objective: To describe the serologic prevalence of antibodies anti-T. cruzi in subjects with low risk for the acquisition of infection via vector. Material and methods: A cross-sectional study in blood donors cohort of Medica Sur. We detected the serum antibodies against T. cruzi. In the initial screening We applying an ELISA test and when the ratio absorbency of serum problem/cut off (RP/PC), was > 0.600 (stratified in < 1.0, 1-1.5, and > 1.5). We confirmed by immunofluorescence indirect (IFI, abnormal titles > 1:16). Results: We studied 8,356 donors, with 27 reactive subjects on screening phase (prevalence 0.32%). When confirming by means of IFI did not obtain reactive results in blood donor. In seven cases, the RP/PC was < 1.0, and in 10 cases for the other two groups. We not observed differences between RP/PC groups and origin geographic zone, blood donor occupation, as well as in age groups or values of erythrocyte index. More than half of the donors already they had donated at least in an occasion (proportion 0.60). Conclusions: The profile of blood donor in Medica Sur, without risk factors to vectorial acquisition of T. cruzi infection, puts in doubt the utility of universal screening in this population.


REFERENCES

  1. WHO Expert Committee. Control of Chagas disease. World Health Organ Tech Rep Ser. 2002; 905: i-vi, 1-109, back cover.

  2. Dias JC, Silveira AC, Schofield CJ. The impact of Chagas disease control in Latin America: a review. Mem Inst Oswaldo Cruz 2002; 97: 603-12.

  3. Moncayo A. Chagas disease: current epidemiological trends after the interruption of vectorial and transfusional transmission in the Southern Cone countries. Mem Inst Oswaldo Cruz 2003; 98: 577-91.

  4. Guía de evaluación de los procesos de control de tratomineos y del control de la transmisión transfusional de T. cruzi (Montevideo Uruguay, 2002). Iniciativa del Cono Sur. OPS/HCP/HCT/193/02.

  5. Schmunis GA. Prevention of transfusional Trypanosoma cruzi infection in Latin America. Mem Inst Oswaldo Cruz 1999; 94 Suppl 1: 93-101.

  6. Velasco CO, Valdespino JL, Tapia CR, Salvatierra B, Guzmán BC, Magos C et al. Seroepidemiology of Chagas disease in Mexico. Salud Publica Mex 1992; 34: 186-96.

  7. Ramos EAA, Monteón PVM, Reyes LPA. Detection of antibodies against Trypanosoma cruzi in blood donors. Salud Publica Mex 1993; 35: 56-64.

  8. García DG, Moreno AL, De Haro AI, Huerta ASG, Salazar SPM. Validation of data collection for an American trypanosomiasis epidemiologic study in the State of Morelos, Mexico. Bol Chil Parasitol 1998; 53: 92-7.

  9. Rangel H, Gatica R, Ramos C. Detection of antibodies against Trypanosoma cruzi in donors from a blood bank in Cuernavaca, Morelos, Mexico. Arch Med Res 1998; 29: 79-82.

  10. 2015: Contreras FT, Yerenas Mde L, Gutierrez MS, Anaya MR, Corder AJ. Serological follow-up of Trypanosoma cruzi infection from 1987 to 1994 in individuals studies in 50 counties of the State of Jalisco, Mexico. Rev Soc Bras Med Trop 2000; 33: 591-6.

  11. Norma Oficial Mexicana NOM-003-SSA2-1993, para la disposición de sangre humana y sus componentes con fines terapéuticos Diario Oficial de la Federación 18 de Julio de 1994.

  12. Schmunis GA, Zicker F, Cruz JR, Cuchi P. Safety of blood supply for infectious diseases in Latin American countries, 1994-1997. Am J Trop Med Hyg 2001; 65: 924-30.

  13. Monteón VM, Guzmán BC, Floriani VJ, Ramos EA, Velasco CO, Reyes PA. Serological diagnosis of Chagas disease: self-sufficiency and interlaboratory concordance. Salud Publica Mex 1995; 37: 232-5.

  14. Langhi DM Jr, Bordin JO, Castelo A, Walter SD, Moraes SH, Stumpf RJ. The application of latent class analysis for diagnostic test validation of chronic Trypanosoma cruzi infection in blood donors. Braz J Infect Dis 2002; 6: 181-7.

  15. Leiby DA, Wendel S, Takaoka DT, Fachini RM, Oliveira LC, Tibbals MA. Serologic testing for Trypanosoma cruzi: comparison of radioimmunoprecipitation assay with commercially available indirect immunofluorescence assay, indirect hemagglutination assay, and enzyme-linked immunosorbent assay kits. J Clin Microbiol 2000; 38: 639-42.

  16. Dumonteil E. Update on Chagas’s disease in Mexico. Salud Publica Mex 1999; 41: 322-7.

  17. Sanchez GMC, Barnabe C, Guegan JF, Tibayrenc M, Velázquez RM, Martínez MJ et al. High prevalence anti-Trypanosoma cruzi antibodies, among blood donors in the State of Puebla, a non-endemic area of Mexico. Mem Inst Oswaldo Cruz 2002; 97: 947-52.

  18. Galel SA, Kirchhoff LV. Risk factors for Trypanosoma cruzi infection in California blood donors. Transfusion 1996; 36: 227-31.

  19. Jiménez CE, Campos VG, Sánchez RL, Castellanos PR, Romero P, Morales AE. PCR and specific antibodies to trypanosoma cruzi en blood-donors at the Central Blood Bank from Centro Médico Nacional de Occidente (IMSS), Guadalajara, Jalisco, México. Bioquimia 2000; 25: 100-104.

  20. Mazariego AMA, Monteón VM, Ballinas VMA, Hernandez BN, Alejandre AR, Reyes PA. Seroprevalence of human Trypanosoma cruzi infection in diferent geographic zones of Chiapas, Mexico. Rev Soc Bras Med Trop 2001; 34: 453-8.

  21. Becerril FMA, Valle-De La Cruz A. Description of Chagas disease in the Valle de Iguala, Guerrero state, Mexico. Gac Med Mex 2003; 139: 539-44.

  22. Rangel FH, Sanchez B, Mendoza DJ, Barnabe C, Breniere FS, Ramos C, Espinoza B. Serologic and parasitologic demonstration of Trypanosoma cruzi infections in an urban area of central Mexico: correlation with electrocardiographic alterations. Am J Trop Med Hyg 2001; 65: 887-95.

  23. Dumonteil E, Gourbiere S, Barrera PM, Rodriguez FE, Ruiz PH, Baños LO, et al. Geographic distribution of Triatoma dimidiata and transmission dynamics of Trypanosoma cruzi in the Yucatan peninsula of Mexico. Am J Trop Med Hyg 2002; 67: 176-83.

  24. Trujillo CF, Lozano KF, Soto GMM, Hernandez GR. The prevalence of Trypanosoma cruzi infection in blood donors in the state of Jalisco, Mexico. Rev Soc Bras Med Trop 1993; 26: 89-92.

  25. Campos VG, Barrera PR, De la Luz SRene, Jiménez CE, Martínez LP. Presencia de la infección por Trypanosoma cruzi en perros de la zona norte del Estado de México. Revista AMMVEPE 1999; 10: 111-113.

  26. Reyes PA, Monteón VM, Hernandez BN. The risk of transfusion transmission of Chagas disease in Mexico City. Transfusion 2000; 40: 613.

  27. Monteón PVM, Hernandez BN, Guzmán BC, Rosales EL, Reyes LPA. American trypanosomiasis (Chagas’ disease) and blood banking in Mexico City: seroprevalence and its potential transfusional transmission risk. Arch Med Res 1999; 30: 393-8.

  28. Hamerschlak N, Pasternak J, Amato Neto V, de Carvalho MB, Guerra CS, Coscina AL et al. Chagas’ disease: an algorithm for donor screening and positive donor counseling. Rev Soc Bras Med Trop 1997; 30: 205-9.

  29. Sanchez B, Monteón V, Reyes PA, Espinoza B. Standardization of micro-enzyme-linked immunosorbent assay (ELISA) and Western blot for detection of Trypanosoma cruzi antibodies using extracts from Mexican strains as antigens. Arch Med Res 2001; 32: 382-8.

  30. Bucio MI, Cabrera M, Segura EL, Zenteno E, Salazar-Schettino M. Identification of immunodominant antigens in Mexican strains of Trypanosoma cruzi. Immunol Invest 1999; 28: 257-68.

  31. Silveira HJ, Mozart ON, Norberg AN, Pile EA. Trypanosoma cruzi prevalence and clinical forms in blood donor candidates in Brazil. Rev Saude Publica 2003; 37: 807-9

  32. Van den Burg PJ, Vrielink H, Reesink HW. Donor selection: the exclusion of high risk donors? Vox Sang 1998; 74 Suppl 2: 499-502.




2020     |     www.medigraphic.com